Andrea Gomez
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Microdosing psychedelics: media attention for mood, creativity, anxiety relief. Explore data on benefits and myths in a critical analysis.
Harriet de Wit, Balázs Szigeti, Eline Haijen
Manoj Doss discusses psychedelic impact on episodic memories, highlighting FLUX theory. Fred Barrett explores psychedelic therapy's potential for lasting shifts in psychological and cognitive flexibility across disorders.
Frederick Barrett, Manoj K. Doss
Overview of a multicenter trial compares psilocybin therapy to active control for demoralization in end-of-life adults. Trial focuses on treating depression, anxiety, and improving quality of life, spiritual well-being, and
Jessi Humphreys
Roland Griffiths, Ph.D., from Johns Hopkins University, leads research on psilocybin's effects, including therapeutic studies for psychological distress, depression, addiction, and brain imaging for neural mechanisms.
Roland Griffiths
5-MeO-DMT, a natural tryptamine, shows psychedelic effects by acting on serotonin receptors. Clinical trials suggest its potential for rapidly reducing depression symptoms, prompting further studies for depression treatment.
Johannes Reckweg
Robin Carhart-Harris, Head of Centre for Psychedelic Research at Imperial College London, conducted pioneering clinical studies with psilocybin and other psychedelic drugs for over 40 years. He collaborates with Professor
Wellness and Psychedelics: Academic studies show psychedelics, in clinical settings with therapy, rapidly improve psychiatric conditions. Survey of 3,000 adults found significant improvements in mental health with psychedelic use.
Saundra Jain
Canadian Psychedelic Survey collected real-world evidence from 2393 Canadian adults on psychedelic use, revealing patterns, effects, and reasons for use. Results may influence policy and treatment approaches.
Philippe Lucas
Elliot Cohen (Pillpack, Amazon) and Protik Basu (World Bank, UN, Helena) share insights on healthcare delivery, psychedelics industry, scaling challenges, and technology's role in patient care.
Andrew “Mo” Septimus, Protik Basu, Elliot Cohen
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.